Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States

References

• Ferreira C, Providencia R, and Ferreira MJ, et al. Atrial fibrillation and con-cardiovascular diseases: a Systematic review. Arq Bras Cardiol. 2015;105(5):519–526.
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, and Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125.
   PubMed Web of Science ®Google Scholar
• Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142–1147.
   PubMed Web of Science ®Google Scholar
• Tsao CW, Aday AW, and Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a Report from the American Heart Association. Circulation. 2022;145(8):e153–e639.
   PubMed Web of Science ®Google Scholar
• Perez MV, Mahaffey KW, and Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909–1917.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–952.
   PubMed Web of Science ®Google Scholar
• Jabre P, Roger VL, and Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation. 2011;123(15):1587–1593.
   PubMed Web of Science ®Google Scholar
• Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol. 2002;155(9):819–826.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Vidaillet H, Granada JF, and Chyou P, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113(5):365–370.
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, and Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020;42(5):373–498.
   Web of Science ®Google Scholar
• Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627–628.
   PubMed Web of Science ®Google Scholar
• Proietti M, Romiti GF, Olshansky B, et al. Comprehensive management with the ABC (Atrial Fibrillation Better Care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J Am Heart Assoc. 2020;9(10):e014932.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, and Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–e76.
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, and Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313–320.
   PubMed Web of Science ®Google Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther. 2009;26(9):847–857.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9(5):348–356.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, and Calkins H, et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Camm AJ, and Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–1316.
   PubMed Web of Science ®Google Scholar
• Kim MH, Lin J, Jhaveri M, et al. Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter. Adv Ther. 2014;31(3):318–332.
   PubMed Web of Science ®Google Scholar
• IBM Watson Health. White Paper: IBM MarketScan Research Databases for life sciences researchers. (2018).
   Google Scholar
• IBM MarketScan. IBM MarketScan Research Databases, (Ed.^(Eds), 2022 https://www.ibm.com/products/marketscan-research-databases/databases. Accessed January 2022.
   Google Scholar
• Kim H, Kim TH, and Cha MJ, et al. A prospective survey of atrial fibrillation management for real-world guideline adherence: cOmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) registry. Korean Circ J. 2017;47(6):877–887.
   PubMed Web of Science ®Google Scholar
• Chang AY, Askari M, and Fan J, et al. Association of healthcare plan with atrial fibrillation prescription patterns. Clin Cardiol. 2018;41(9):1136–1143.
   PubMed Web of Science ®Google Scholar
• Proietti M, Laroche C, and Opolski G, et al. ‘Real-world’ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace. 2017;19(5):722–733.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, and Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Mansour M, Heist EK, and Agarwal R, et al. Stroke and cardiovascular events after ablation or antiarrhythmic drugs for treatment of patients with atrial fibrillation. Am J Cardiol. 2018;121(10):1192–1199.
   PubMed Web of Science ®Google Scholar
• Willems S, Borof K, and Brandes A, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2021. DOI:https://doi.org/10.1093/eurheartj/ehab593.
   Google Scholar
• Rillig A, Magnussen C, and Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation. 2021;144(11):845–858.
   PubMed Web of Science ®Google Scholar
• Andrade JG, Wells GA, and Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384(4):305–315.
   PubMed Web of Science ®Google Scholar
• Wazni OM, Dandamudi G, and Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384(4):316–324.
   PubMed Web of Science ®Google Scholar
• Packer DL, Mark DB, and Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261–1274.
   PubMed Web of Science ®Google Scholar
• Chew D, Cowper P, and Li Y, et al. Economic outcomes of ablation versus drug therapy in CABANA. 2021 Heart Rhythm Society annual meeting. Boston and Virtual; 2021.
   Google Scholar
• Hohnloser SH, Crijns HJ, and van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668–678.
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Crijns HJ, and Gaudin C, et al. Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace. 2011;13(8):1118–1126.
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Lavelle T, Essebag V, et al. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006;152(6):1097–1103.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Sugrue A, Asirvatham S. Atrial fibrillation: beyond rate control. Mayo Clin Proc. 2018;93(3):373–380.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Mañero M, Sarkozy A, and Chierchia GB, et al. Prophylactic antiarrhythmic drug therapy in atrial fibrillation. J Atr Fibrillation. 2013;5(5):108–123.
   Google Scholar
• Steen DL, Khan I, Ansell D, et al. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open. 2017;7(2):e013255.
   PubMed Web of Science ®Google Scholar
• Blomström-Lundqvist C, Marrouche N, and Connolly S, et al. Efficacy and safety of dronedarone by atrial fibrillation history duration: insights from the ATHENA study. Clin Cardiol. 2020;43(12):1469–1477.
   PubMed Web of Science ®Google Scholar